|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.98 USD | -0.83% |
|
-10.91% | -31.94% |
| 06-11 | Silo Pharma, Inc. announced that it has received $2.077409 million in funding | CI |
| 06-07 | Silo Pharma Close to Achieving Optimal Formulation for Ketamine Implant | MT |
Silo Pharma, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 0.801667 million compared to USD 0.906396 million a year ago. Basic loss per share from continuing operations was USD 0.28 compared to USD 0.29 a year ago.
Diluted loss per share from continuing operations was USD 0.28 compared to USD 0.29 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -31.94% | 3.64M | |
| +2.22% | 93.53B | |
| -1.32% | 38.27B | |
| -13.44% | 32.84B | |
| +76.30% | 27.83B | |
| -13.11% | 16.08B | |
| +0.68% | 14.02B | |
| -12.06% | 11.47B | |
| +185.28% | 9.92B | |
| -53.00% | 9.42B |
SILO PHARMA, INC. 
